GO:0004812 aminoacyl-tRNA ligase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004812 aminoacyl-tRNA ligase activity is the catalytic function that attaches an amino acid to its cognate tRNA using ATP, releasing AMP and diphosphate.
• This activity is essential for translation because it ensures that each codon is paired with the correct amino acid, thereby maintaining proteome fidelity.
• Aminoacyl-tRNA synthetases are not limited to translation; they also participate in cell signaling, immune regulation, and disease progression.
• Mutations in aminoacyl-tRNA synthetase genes such as NARS1 cause neurodevelopmental delay through toxic gain-of-function and partial loss-of-function mechanisms.
• In melanoma, valine aminoacyl-tRNA synthetase (VARS) promotes therapy resistance, linking this activity to cancer drug response.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of aminoacyl-tRNA ligase activity in health and disease.
Description
Aminoacyl-tRNA ligase activity (GO:0004812) is a fundamental molecular function that catalyzes the formation of aminoacyl-tRNA from ATP, an amino acid, and tRNA, with the release of diphosphate and AMP. This reaction, often called tRNA aminoacylation or tRNA charging, is the first step of protein synthesis and is carried out by a family of enzymes known as aminoacyl-tRNA synthetases (ARSs). Because each ARS pairs a specific amino acid with its corresponding tRNA, this activity is central to the fidelity of translation and to the coupling of the genetic code with the proteome. Beyond translation, ARSs have been implicated in cell signaling, immune responses, and disease, making GO:0004812 a high-value target for basic and translational research. Researchers study aminoacyl-tRNA ligase activity to understand how cells maintain proteostasis, how mutations in ARS genes cause human disease, and how cancer cells rewire translation to survive therapy. The activity is also a node for regulation by nutrients, stress, and signaling pathways, and it is increasingly recognized as a source of non-canonical functions. In this article, we integrate the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanism, genes, disease links, and experimental models relevant to GO:0004812.
aminoacyl-tRNA ligase activity At A Glance
| GO ID | GO:0004812 |
|---|---|
| GO term | aminoacyl-tRNA ligase activity |
| Ontology | molecular_function |
| Synonym | aminoacyl-tRNA synthetase activity; aminoacyl-tRNA synthetase auxiliary protein activity; ligase activity, forming aminoacyl-tRNA and related compounds |
| Definition | Catalysis of the formation of aminoacyl-tRNA from ATP, amino acid, and tRNA with the release of diphosphate and AMP. |
| Major function | Charging tRNA with cognate amino acids for translation and non-canonical signaling roles. |
| EC number | 6.1.1.- (aminoacyl-tRNA ligases) |
| Reaction | ATP + amino acid + tRNA → aminoacyl-tRNA + AMP + diphosphate. |
| Cellular context | Cytoplasm and mitochondria; often part of multi-synthetase complexes. |
What Is GO:0004812?
GO:0004812 aminoacyl-tRNA ligase activity is defined by QuickGO as the catalysis of the formation of aminoacyl-tRNA from ATP, an amino acid, and tRNA, with the release of diphosphate and AMP. In other words, it is the enzymatic activity that charges a tRNA molecule with its correct amino acid, a prerequisite for ribosomal protein synthesis. This activity is synonymous with aminoacyl-tRNA synthetase activity and is classified as a molecular function in the Gene Ontology.
Why Is aminoacyl-tRNA ligase activity Important in Cell Biology?
Aminoacyl-tRNA ligase activity is essential for life because it establishes the molecular link between the genetic code and protein sequence. Without accurate tRNA charging, translation would be error-prone, leading to proteotoxic stress and disease. Beyond its canonical role, this activity contributes to cell signaling, immune regulation, and cancer therapy resistance, making it a focal point for understanding both fundamental biology and human pathologies.
• Ensures translational fidelity by pairing each tRNA with its correct amino acid.
• Provides the first step of protein synthesis and is required for cell growth and proliferation.
• Mutations in ARS genes cause neurodevelopmental disorders such as NARS1-related delay.
• VARS promotes therapy resistance in melanoma, linking charging activity to drug response.
• ARSs participate in cell signaling pathways beyond translation.
• Multi-synthetase complexes coordinate translation and non-translational functions.
• Enzymes like peptide-aminoacyl-tRNA ligases expand the functional repertoire of this activity.
• Structural dynamics such as half-of-the-sites activity regulate catalytic efficiency.
• Engineering ARS activity can enhance biosynthesis of branched-chain amino acids.
• Machine-learning approaches can activate proteins in living mice, including ARS-related pathways.
What Happens During aminoacyl-tRNA ligase activity?
Substrate binding and amino acid activation
In simple terms: The enzyme first grabs the amino acid and ATP, then activates the amino acid by attaching AMP to it.
Aminoacyl-tRNA synthetases bind a specific amino acid and ATP in their catalytic site. The amino acid is activated by adenylation, forming an aminoacyl-AMP intermediate with release of diphosphate. This step is highly specific and is a key checkpoint for fidelity. Structural studies show that homodimeric synthetases can exhibit half-of-the-sites activity, where only one subunit is active at a time, influencing overall catalytic rate.
tRNA recognition and aminoacyl transfer
In simple terms: The activated amino acid is then transferred onto the correct tRNA molecule.
The activated aminoacyl-AMP is transferred to the 3' end of the cognate tRNA, forming aminoacyl-tRNA and releasing AMP. tRNA identity elements, such as the anticodon and acceptor stem, ensure that only the correct tRNA is charged. This step is critical for translating the genetic code accurately. Some synthetases use editing domains to hydrolyze mischarged tRNAs, further enhancing fidelity.
Release of products and recycling
In simple terms: After charging the tRNA, the enzyme releases the products and is ready for another round.
Following aminoacyl transfer, the charged tRNA and AMP are released, and the enzyme returns to its initial state for another catalytic cycle. The reaction consumes ATP and produces AMP and diphosphate, making it energetically costly. This cycle is repeated thousands of times per second in rapidly growing cells. The efficiency of this cycle can be modulated by structural fluctuations and subunit interactions.
Non-canonical roles and signaling
In simple terms: Some of these enzymes also have second jobs outside of translation.
Beyond tRNA charging, aminoacyl-tRNA synthetases can act as signaling molecules, regulate immune responses, and participate in angiogenesis and apoptosis. They often form multi-synthetase complexes that coordinate translation with other cellular processes. For example, VARS promotes therapy resistance in melanoma, demonstrating a non-canonical role in cancer. These functions expand the biological importance of GO:0004812 beyond protein synthesis.
Key Genes Involved in GO:0004812 aminoacyl-tRNA ligase activity
The following genes encode aminoacyl-tRNA synthetases and related proteins that carry out or regulate GO:0004812 activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AARS1 | Alanyl-tRNA synthetase; charges tRNA-Ala | Mutations linked to neurodevelopmental disorders; model for fidelity |
| NARS1 | Asparaginyl-tRNA synthetase; charges tRNA-Asn | De novo variants cause neurodevelopmental delay |
| VARS1 | Valyl-tRNA synthetase; charges tRNA-Val | Promotes therapy resistance in melanoma |
| LARS1 | Leucyl-tRNA synthetase; charges tRNA-Leu | Regulates mTOR signaling; cancer and immunity |
| IARS1 | Isoleucyl-tRNA synthetase; charges tRNA-Ile | Growth retardation and metabolic defects |
| MARS1 | Methionyl-tRNA synthetase; charges tRNA-Met | Charcot-Marie-Tooth disease and lung disease |
| GARS1 | Glycyl-tRNA synthetase; charges tRNA-Gly | Charcot-Marie-Tooth disease type 2D |
| YARS1 | Tyrosyl-tRNA synthetase; charges tRNA-Tyr | Dominant-intermediate Charcot-Marie-Tooth disease |
| KARS1 | Lysyl-tRNA synthetase; charges tRNA-Lys | Neurodevelopmental and hearing loss |
| SARS1 | Seryl-tRNA synthetase; charges tRNA-Ser | Neurodevelopmental delay and microcephaly |
| DARS1 | Aspartyl-tRNA synthetase; charges tRNA-Asp | Hypomyelination with brainstem and spinal cord involvement |
| EPRS1 | Glutamyl-prolyl-tRNA synthetase; charges tRNA-Glu/Pro | Multisynthetase complex; immune regulation |
| MARS2 | Mitochondrial methionyl-tRNA synthetase | Mitochondrial translation and disease |
| FARS2 | Mitochondrial phenylalanyl-tRNA synthetase | Mitochondrial encephalopathy |
| TARS1 | Threonyl-tRNA synthetase; charges tRNA-Thr | Angiogenesis and cancer |
| WARS1 | Tryptophanyl-tRNA synthetase; charges tRNA-Trp | Immune modulation and cancer |
| HARS1 | Histidyl-tRNA synthetase; charges tRNA-His | Usher syndrome and neuropathy |
How Is aminoacyl-tRNA ligase activity Regulated?
Aminoacyl-tRNA ligase activity is regulated at multiple levels. Nutrient availability and mTOR signaling influence the expression and activity of several ARSs, particularly LARS1, which acts as a leucine sensor for mTORC1. The integrated stress response can modulate tRNA charging and synthetase expression to adapt to stress. Multi-synthetase complexes provide spatial and temporal regulation, coordinating translation with other cellular functions. Post-translational modifications and structural dynamics, such as half-of-the-sites activity, further tune catalytic output. In cancer, VARS expression is upregulated and contributes to therapy resistance, indicating disease-specific regulation.
aminoacyl-tRNA ligase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NARS1 | Neurodevelopmental delay with toxic gain-of-function and partial loss-of-function | Knock-in mouse or patient iPSC-derived neurons |
| VARS1 | Melanoma therapy resistance | CRISPR knockout in melanoma cell lines; xenograft models |
| LARS1 | mTOR signaling and cancer | Knockout or point-mutation cell lines; mouse models |
| FARS2 | Mitochondrial encephalopathy | Knockout zebrafish or mouse; mitochondrial assays |
| GARS1 | Charcot-Marie-Tooth disease | Knock-in mouse models; neuronal cultures |
Neurodevelopmental disorders
Mutations in aminoacyl-tRNA synthetase genes are increasingly recognized as causes of neurodevelopmental delay. For example, de novo and bi-allelic pathogenic variants in NARS1 cause neurodevelopmental delay through toxic gain-of-function and partial loss-of-function effects. Other ARS genes such as AARS1, KARS1, and SARS1 are also linked to neurological phenotypes, highlighting the sensitivity of the nervous system to translation defects.
Cancer and therapy resistance
Aminoacyl-tRNA synthetases can promote cancer progression and drug resistance. Valine aminoacyl-tRNA synthetase (VARS) promotes therapy resistance in melanoma, and its inhibition can restore sensitivity to targeted therapies. Other ARSs, such as LARS1 and TARS1, are implicated in cancer cell growth and angiogenesis, making them potential therapeutic targets.
Mitochondrial and metabolic disease
Mitochondrial aminoacyl-tRNA synthetases are essential for mitochondrial translation, and mutations in genes such as FARS2 and MARS2 cause mitochondrial encephalopathies and metabolic disorders. Additionally, engineering ARS activity can enhance branched-chain amino acid biosynthesis, linking this activity to metabolic engineering.
From aminoacyl-tRNA ligase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ARS gene affect translation and viability? | CRISPR knockout cell lines (e.g., HEK293, HeLa) |
| Does a disease-associated point mutation alter charging activity? | Point-mutation knock-in via CRISPR |
| Can a tagged ARS be used to study localization and interactions? | Knock-in of FLAG/GFP tag |
| Does overexpression of VARS confer therapy resistance? | Overexpression cell lines and xenografts |
| What is the impact of ARS mutations on neuronal development? | Patient iPSC-derived neurons or organoids |
| Can ARS activity be engineered for metabolic production? | CRISPR-directed evolution or base editing |
How to Study the aminoacyl-tRNA ligase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| tRNA aminoacylation assay | Catalytic activity of ARS enzymes | Enzyme kinetics and inhibitor testing |
| X-ray crystallography / cryo-EM | Three-dimensional structure | Substrate binding and mechanism |
| Ribo-seq | Translation efficiency and codon occupancy | Global impact of ARS perturbation |
| RNA-seq | Transcriptional changes | Pathway analysis after knockout |
| Proteomics | Protein interactions and modifications | Multi-synthetase complex composition |
| CRISPR knockout screen | Gene essentiality and drug resistance | Identify ARS dependencies in cancer |
| Machine-learning protein activation | Functional activation in vivo | Therapeutic protein activation |
| Metabolic engineering | Branched-chain amino acid production | Strain improvement |
Biochemical assays for tRNA charging
Aminoacylation assays using radiolabeled amino acids or fluorescent tRNA probes measure the catalytic activity of ARSs directly. These assays can be performed with purified enzymes or cell lysates to determine kinetic parameters and inhibitor sensitivity.
Structural and biophysical methods
X-ray crystallography, cryo-EM, and NMR spectroscopy reveal the structural basis of substrate recognition and catalysis. For example, structural fluctuation studies have shown half-of-the-sites activity in homodimeric synthetases. These methods guide the design of inhibitors and engineered variants.
Omics and systems approaches
Ribo-seq and RNA-seq can assess the impact of ARS perturbations on translation and gene expression. Proteomics identifies interacting partners and post-translational modifications. Machine-learning approaches are emerging to predict and activate protein function in vivo.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify ARS genes required for cell growth, drug resistance, or immune evasion. These screens link GO:0004812 activity to specific phenotypes and can uncover synthetic lethal interactions.
How CRISPR Can Be Used to Study GO:0004812 aminoacyl-tRNA ligase activity
Knockout
CRISPR knockout of ARS genes can reveal their essentiality and impact on translation. For example, knocking out VARS in melanoma cells can reverse therapy resistance. Knockout models are also used to study loss-of-function effects of disease-associated variants.
Point Mutation
Introducing disease-associated point mutations (e.g., in NARS1) via CRISPR base editing or homology-directed repair allows precise modeling of toxic gain-of-function or partial loss-of-function effects. These models help dissect allele-specific mechanisms.
Knock-in
Knock-in of tags (e.g., FLAG, GFP) or reporter cassettes enables visualization and purification of ARS proteins. Knock-in of patient mutations into endogenous loci provides physiological expression levels for accurate phenotyping.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can model ARS upregulation observed in cancers. Overexpression of VARS confers therapy resistance, and such models are used to test combination therapies. Overexpression also facilitates biochemical purification of ARS complexes.
How EDITGENE Supports aminoacyl-tRNA ligase activity Research
Researchers studying aminoacyl-tRNA ligase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as drug resistance or neurodevelopmental delay. This requires precise genetic models that can knockout, mutate, tag, or overexpress the gene of interest in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for aminoacyl-tRNA ligase activity research.
Frequently Asked Questions About aminoacyl-tRNA ligase activity
What is aminoacyl-tRNA ligase activity?
Aminoacyl-tRNA ligase activity (GO:0004812) is the enzymatic function that attaches an amino acid to its corresponding tRNA using ATP, releasing AMP and diphosphate. This charging reaction is essential for protein synthesis.
What genes are involved in aminoacyl-tRNA ligase activity?
Genes encoding aminoacyl-tRNA synthetases, such as AARS1, NARS1, VARS1, LARS1, and MARS1, carry out this activity. Each gene encodes an enzyme specific for one amino acid.
How is aminoacyl-tRNA ligase activity regulated?
It is regulated by nutrient signaling (e.g., mTORC1 via LARS1), the integrated stress response, multi-synthetase complex formation, and post-translational modifications.
What diseases are linked to aminoacyl-tRNA ligase mutations?
Mutations in ARS genes cause neurodevelopmental disorders (e.g., NARS1), Charcot-Marie-Tooth disease (GARS1, YARS1), and mitochondrial encephalopathies (FARS2). VARS is linked to melanoma therapy resistance.
How can I study aminoacyl-tRNA ligase activity in the lab?
Common methods include tRNA aminoacylation assays, structural biology, Ribo-seq, proteomics, and CRISPR screens. These approaches measure catalytic activity, translation impact, and genetic dependencies.
What is the role of VARS in cancer?
VARS (valine aminoacyl-tRNA synthetase) promotes therapy resistance in melanoma, and its inhibition can restore drug sensitivity.
Can CRISPR be used to model aminoacyl-tRNA synthetase mutations?
Yes, CRISPR knockout, point-mutation knock-in, and overexpression models are widely used to study ARS gene function and disease mechanisms.
What is the difference between aminoacyl-tRNA ligase and aminoacyl-tRNA synthetase?
They refer to the same activity; aminoacyl-tRNA synthetase is a synonym for aminoacyl-tRNA ligase activity (GO:0004812).
What is the reaction catalyzed by aminoacyl-tRNA ligase?
ATP + amino acid + tRNA → aminoacyl-tRNA + AMP + diphosphate. This two-step reaction involves amino acid activation and tRNA charging.
Why is aminoacyl-tRNA ligase activity important for translation?
It ensures that each tRNA is charged with the correct amino acid, which is necessary for accurate translation of the genetic code into proteins.
Conclusion
Aminoacyl-tRNA ligase activity (GO:0004812) is a cornerstone of protein synthesis and a hub for cellular signaling, disease, and therapeutic innovation. From neurodevelopmental disorders caused by NARS1 mutations to melanoma therapy resistance driven by VARS, this activity has broad biomedical relevance. Understanding its mechanism, regulation, and genetic dependencies requires robust experimental models. CRISPR-based knockout, point-mutation, knock-in, and overexpression systems, combined with multi-omics and screening approaches, provide the tools needed to dissect this essential function. EDITGENE offers comprehensive services to accelerate research on aminoacyl-tRNA ligase activity and its role in health and disease.
References
- 1. El-Hachem N et al.. 2024. Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma.. Nat Cell Biol 26(7):1154-1164 PMID: 38849541
- 2. Ramos-Figueroa J et al.. 2025. Substrate recognition by a peptide-aminoacyl-tRNA ligase.. Proc Natl Acad Sci U S A 122(12):e2423858122 PMID: 40106349
- 3. Okamoto Y et al.. 2024. Structural Fluctuation in Homodimeric Aminoacyl-tRNA Synthetases Induces Half-of-the-Sites Activity.. J Phys Chem B 128(44):10823-10830 PMID: 39441699
- 4. Manole A et al.. 2020. De Novo and Bi-allelic Pathogenic Variants in NARS1 Cause Neurodevelopmental Delay Due to Toxic Gain-of-Function and Partial Loss-of-Function Effects.. Am J Hum Genet 107(2):311-324 PMID: 32738225
- 5. Wang X et al.. 2025. Machine-learning-assisted universal protein activation in living mice.. Cell 188(14):3696-3714.e24 PMID: 40436016
- 6. Derunets AS et al.. 2026. Engineering aminoacyl-tRNA synthetase activity to enhance branched-chain amino acid biosynthesis.. Biochimie 246:21-30 PMID: 41933685
- 7. Yao P et al.. 2020. Aminoacyl-tRNA synthetases in cell signaling.. Enzymes 48:243-275 PMID: 33837706
- 8. Lee SW et al.. 2004. Aminoacyl-tRNA synthetase complexes: beyond translation.. J Cell Sci 117(Pt 17):3725-34 PMID: 15286174
